Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: An analytical and comprehensive overview

RMD Open

Volumn 2, Issue 2, 2016, Pages

  Toussirot, Éric ^a,b   Aubin, François ^a,c  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b Hôpital Saint Jacques   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84987934427     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2015-000239     Document Type: Review

References (81)

1. Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Expert Rev Clin Immunol 2009;5:421-31.
2. Toussirot E, Pertuiset E. TNFα blocking agents and sarcoidosis: an update. Rev Med Interne 2010;31:828-37.
3. Joyau C, Veyrac G, Dixneuf V, et al. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? Clin Exp Rheumatol 2012;30:700-6.
4. Fouache D, Goëb V, Massy-Guillemant N, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 2009;48:761-4.
5. Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76.
6. Baeten D, Kruithof E, Van den Bosch F, et al. Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829-34.
7. Collamer AN, Guerrero KT, Henning JS, et al. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
8. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010;40:233-40.
9. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010;8:1048-55.
10. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-15.
11. Hernandez MV, Sanmarti R, Canete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res 2013;65:2024-31.
12. Jimenez-Boj E, Stamm TA, Sadlonova M, et al. Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 2012;71:1868-71.
13. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007;56:2715-18.
14. Thomas L, Canoui-Poitrine F, Gottenberg JE, et al. Incidence of new-onset and flare of preexisting psoriasis during rituximab therapy for rheumatoid arthritis: data from the French AIR registry. J Rheumatol 2012;39:893-8.
15. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48.
16. Jost C, Hermann J, Caelen Lel-S, et al. New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis. BMJ Case Rep 2009;2009:pii:bcr09.2008.0845.
17. Kato K, Satoh T, Nishizawa A, et al. Psoriasiform drug eruption due to abatacept. Acta Derm Venereol 2011;91:362-3.
18. Florent A, Albert C, Giacchero D, et al. Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy. Joint Bone Spine 2010;77:626-7.
19. Brunasso AM, Laimer M, Massone C. Paradoxical reactions to targeted biological treatments: a way to treat and trigger? Acta Derm Venereol 2010;90:183-5.
20. Laurent S, Le Parc JM, Clérici T, et al. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol 2010;163:1364-5.
21. Palmou-Fontana N, Sánchez Gaviño JA, McGonagle D, et al. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology (Basel) 2014;228:311-13.
22. Puig L, Morales-Múnera CE, López-Ferrer A, et al. Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology (Basel) 2012;225:14-17.
23. Hay RA, Pan JY. Paradoxical flare of pustular psoriasis triggered by ustekinumab, which responded to adalimumab therapy. Clin Exp Dermatol 2014;39:751-2.
24. Viguier M, Richette P, Aubin F, et al. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. Arthritis Rheum 2008;58:1796-802.
25. Čarija, A, Ivić I, Marasović-Krstulović D, et al. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab. Rheumatology (Oxford) 2015;54:2114-16.
26. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012;9:496-503.
27. Kelly G, Sweeney CM, Tobin AM, et al. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol 2014;53:1186-96.
28. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012;157:846-55.
29. Pellegrino M, Taddeucci P, Peccianti C, et al. Etanercept induced hidradenitis suppurativa. G Ital Dermatol Venereol 2011;146:503-4.
30. Delobeau M, Abdou A, Puzenat E, et al. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa. J Dermatolog Treat 2016;27:251-3.
31. Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biological agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol 2016;74:1153-9.
32. Toussirot É, Houvenagel É, Goëb V, et al. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series. Joint Bone Spine 2012;79:457-63.
33. van Dijken TD, Vastert SJ, Gerloni VM, et al. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 2011;38:1441-6.
34. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127:819-22.
35. Galor A, Perez VL, Hammel JP, et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23.
36. Guignard S, Gossec L, Salliot C, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis 2006;65:1631-4.
37. Rudwaleit M, Rødevand E, Holck P, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696-701.
38. Braun J, Baraliakos X, Listing J, et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51.
39. Le Garrec J, Marcelli C, Mouriaux F. Can tumor necrosis factor inhibitors induce sclero-uveitis? J Fr Ophtalmol 2009;32:511.e1-6.
40. Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, et al. Do TNF-blockers reduce or induce uveitis? Rheumatology (Oxford) 2008;47:731-2.
41. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248-52.
42. Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011;41:503-10.
43. Lie E, Lindström U, Zverkova-Sandström T, et al. The Effect of TNF inhibitor treatment on occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Arthritis Rheum 2015;67:1271-2.
44. Foeldvari I, Becker I, Horneff G. Uveitis events during adalimumab, etanercept, and methotrexate therapy in Juvenile idiopathic arthritis: data from the biologics in pediatric rheumatology registry. Arthritis Care Res (Hoboken) 2015;67:1529-35.
45. Heiligenhaus A, Miserocchi E, Heinz C, et al. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011;50:1390-4.
46. Sen HN, Sangave A, Hammel K, et al. Infliximab for the treatment of active scleritis. Can J Ophthalmol 2009;44:e9-e12.
47. Gaujoux-Viala C, Giampietro C, Gaujoux T, et al. Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 2012;39:233-9.
48. Suhler EB, Lim LL, Beardsley RM, et al. Rituximab therapy for refractory scleritis: results of a phase I/II dose-ranging, randomized, clinical trial. Ophthalmology 2014;121:1885-91.
49. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802.
50. Baughman RP, Lower EE, Bradley DA, et al. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005;128:1062-47.
51. Toussirot E, Pertuiset E, Kantelip B, et al. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases. Clin Exp Rheumatol 2008;26:471-5.
52. Daïen CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009;48:883-6.
53. Min MS, Lebwohl M. Treatment of recalcitrant granuloma annulare (GA) with adalimumab: a single-center, observational study. JAm Acad Dermatol 2016;74:127-3.
54. Voulgari PV, Markatseli TE, Exarchou SA, et al. Granuloma annulare induced by anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:567-70.
55. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. Arch Dermatol 2006;142:198-202.
56. Toussirot E, Berthelot JM, Pertuiset E, et alPulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. J Rheumatol 2009;36:2421-7.
57. Glace B, Gottenberg JE, Mariette X, et al. Efficacy of rituximab in the treatment of pulmonary rheumatoid nodules: findings in 10 patients from the French AutoImmunity and Rituximab/Rheumatoid Arthritis registry (AIR/PR registry). Ann Rheum Dis 2012;71:1429-31.
58. Al Attia HM, Abushawish M. Treatment with tocilizumab leads to the disappearance of olecranon rheumatoid nodules. Int J Dermatol 2012;51:197-8.
59. Andres M, Vela P, Romera C. Marked improvement of lung rheumatoid nodules after treatment with tocilizumab. Rheumatology (Oxford) 2012;51:1132-4.
60. Grau RG. Drug-induced vasculitis: new insights and a changing lineup of suspects. Curr Rheumatol Rep 2015;17:71.
61. Sokumbi O, Wetter DA, Makol A, et al. Vasculitis associated with tumor necrosis factor-α inhibitors. Mayo Clin Proc 2012;87:739-45.
62. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73:710-13.
63. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J Rheumatol 2004;31:1955-8.
64. Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview. Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011;65:473-91.
65. Lv Y, Li Q, Wang L, et al. Use of anti-tumor necrosis factor agents: a possible therapy for vitiligo. Med Hypotheses 2009;72:546-7.
66. Simón JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankylosing spondylitis treated with infliximab. Dermatology 2008;216:234-5.
67. Ramírez-Hernández M, Marras C, Martínez-Escribano JA. Infliximab-induced vitiligo. Dermatology 2005;210:79-80.
68. Toussirot E, Salard D, Algros MP, et al. Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab. Ann Dermatol Venereol 2013;140:801-2.
69. Posada C, Flórez A, Batalla A, et al. Vitiligo during treatment of Crohn's disease with adalimumab: adverse Effect or co-occurrence? Case Rep Dermatol 2011;3:28-31.
70. Mery-Bossard L, Bagny K, Charby G, et al. New onset vitiligo and progression of pre-existing vitilligo during treatment with biological agents in chronic inflammatory diseases. J Eur Acad Dermatol Venereol 2016; [Epub ahead of Print 13 Jun 2016]
71. Tauber M, Buche S, Reygagne P, et al. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 2014;70:1146-9.
72. Grine L, Dejager L, Libert C, et al. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev 2015;26:25-33.
73. Seneschal J, Milpied B, Vergier B, et al. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. Br J Dermatol 2009;161:1081-8.
74. Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005;102:3372-7.
75. Blanco P, Palucka AK, Pascual V, et al. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008;19:41-52.
76. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum 2007;56:3995-4004.
77. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-7.
78. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor - a agents. Arthritis Rheum 2007;57:639-47.
79. Chatterjee S, Eby JM, Al-Khami AA. et al. A quantitative increase in regulatory T cells controls development of vitiligo. J Invest Dermatol 2014;134:1285-94.
80. Baeten D, Van Damme N, Van den Bosch F, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Ann Rheum Dis 2001;60:750-5.
81. Zou J, Rudwaleit M, Brandt J, et al. Upregulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003;62:561-4.